Asthma phenotypes and lung function up to 16 years of age-the BAMSE cohort (vol 70, pg 667, 2015)

被引：0

|

作者：

Hallberg, J.

Thunqvist, P.

Schultz, E. S.

Kull, I

Bottai, M.

Merritt, A-S

Chiesa, F.

Gustafsson, P. M.

Melen, E.

机构：

来源：

ALLERGY | 2016年 / 71卷 / 08期

关键词：

D O I：

10.1111/all.12936

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

引用

收藏

页码：1228 / 1229

页数：2

相关论文

共 24 条

[21] Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: Results of a Phase II trial (vol 31, pg 1330, 2013)
Reynolds, Craig
Spira, Alexander I.
Gluck, Larry
Bradie-Muller, Suzanne J.
Zhan, Feng
Boehm, Kristi A.
Asmar, Lina
INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1628 - 1628
[22] RENAL-FUNCTION UP TO 16 YEARS AFTER CONDUIT (REFLUXING OR ANTIREFLUX ANASTOMOSIS) OR CONTINENT URINARY-DIVERSION .1. GLOMERULAR-FILTRATION RATE AND PATENCY OF URETEROINTESTINAL ANASTOMOSIS (VOL 76, PG 539, 1995)
KRISTJANSSON, A
WALLIN, L
MANSSON, W
BRITISH JOURNAL OF UROLOGY, 1995, 76 (06): : 815 - 815
[23] A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age ≥ 70 years) with Stage IIIB/IV Non-Small Cell Lung Cancer (vol 8, pg 443, 2013)
Stinchcombe, T. E.
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (06) : 814 - 814
[24] Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase3 study (vol 13, pg 141, 2025)
Lena, H.
Greiller, L.
Cropet, C.
LANCET RESPIRATORY MEDICINE, 2025, 13 (02): : e11 - e11